Moleculin Biotech (NASDAQ:MBRX) Rating Lowered to Hold at Maxim Group

Moleculin Biotech (NASDAQ:MBRX) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating in a report issued on Wednesday,Briefing.com Automated Import reports.

Separately, StockNews.com started coverage on Moleculin Biotech in a research note on Sunday. They set a “sell” rating for the company.

Moleculin Biotech Stock Performance

Shares of NASDAQ MBRX opened at $0.51 on Wednesday. The company has a 50 day simple moving average of $1.80 and a 200-day simple moving average of $2.28. Moleculin Biotech has a 1 year low of $0.50 and a 1 year high of $10.35.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.